BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 18473733)

  • 21. Serum markers in early-stage and locally advanced melanoma.
    Lugowska I; Kowalska M; Fuksiewicz M; Kotowicz B; Mierzejewska E; Koseła-Paterczyk H; Szamotulska K; Rutkowski P
    Tumour Biol; 2015 Nov; 36(11):8277-85. PubMed ID: 26002577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors.
    Śmigielski J; Piskorz Ł; Talar-Wojnarowska R; Malecka-Panas E; Jabłoński S; Brocki M
    World J Surg Oncol; 2013 Jun; 11():137. PubMed ID: 23768069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum MMP-8 and TIMP-1 as prognostic biomarkers in gastric cancer.
    Laitinen A; Hagström J; Mustonen H; Kokkola A; Tervahartiala T; Sorsa T; Böckelman C; Haglund C
    Tumour Biol; 2018 Sep; 40(9):1010428318799266. PubMed ID: 30192205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix [corrected] metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer.
    Kirman I; Jain S; Cekic V; Belizon A; Balik E; Sylla P; Arnell T; Forde KA; Whelan RL
    Surg Endosc; 2006 Mar; 20(3):482-6. PubMed ID: 16432654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.
    Böckelman C; Beilmann-Lehtonen I; Kaprio T; Koskensalo S; Tervahartiala T; Mustonen H; Stenman UH; Sorsa T; Haglund C
    BMC Cancer; 2018 Jun; 18(1):679. PubMed ID: 29929486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
    Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
    Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
    Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
    Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
    Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
    Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Elevated serum concentrations of metalloproteinases (MMP-2, MMP-9) and their inhibitors (TIMP-1, TIMP-2) in patients with Graves' orbitopathy.
    Kapelko-Słowik K; Słowik M; Szaliński M; Dybko J; Wołowiec D; Prajs I; Bohdanowicz-Pawlak A; Biernat M; Urbaniak-Kujda D
    Adv Clin Exp Med; 2018 Jan; 27(1):99-103. PubMed ID: 29521049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy.
    Szarvas T; Becker M; Vom Dorp F; Meschede J; Scherag A; Bánkfalvi A; Reis H; Schmid KW; Romics I; Rübben H; Ergün S
    Int J Cancer; 2011 Mar; 128(6):1486-92. PubMed ID: 20473942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activities and polymorphisms of MMP-2 and MMP-9, smoking, diabetes and risk of prostate cancer.
    Kiani A; Kamankesh M; Vaisi-Raygani A; Moradi MR; Tanhapour M; Rahimi Z; Elahi-Rad S; Bahrehmand F; Aliyari M; Aghaz F; Mozafari H; Rezvani N; Haghnazari L; Pourmotabbed T
    Mol Biol Rep; 2020 Dec; 47(12):9373-9383. PubMed ID: 33165815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreases in plasma MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios in uremic patients during hemodialysis.
    Lu LC; Yang CW; Hsieh WY; Chuang WH; Lin YC; Lin CS
    Clin Exp Nephrol; 2016 Dec; 20(6):934-942. PubMed ID: 26711243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C.
    Lichtinghagen R; Huegel O; Seifert T; Haberkorn CI; Michels D; Flemming P; Bahr M; Boeker KH
    Clin Chem; 2000 Feb; 46(2):183-92. PubMed ID: 10657374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study.
    Thorsen SB; Christensen SL; Würtz SO; Lundberg M; Nielsen BS; Vinther L; Knowles M; Gee N; Fredriksson S; Møller S; Brünner N; Schrohl AS; Stenvang J
    BMC Cancer; 2013 Dec; 13():598. PubMed ID: 24330623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
    Brehmer B; Biesterfeld S; Jakse G
    Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival.
    Ozden F; Saygin C; Uzunaslan D; Onal B; Durak H; Aki H
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1373-82. PubMed ID: 23708302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
    Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
    J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression.
    Skerenova M; Mikulova V; Capoun O; Zima T; Tesarova P
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):272-280. PubMed ID: 28529342
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
    Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
    Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.